Attention Deficit Hyperactivity Disorder Therapeutics Market
Global Market Study on Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics: Increasing Production of Generic ADHD Drugs to Boost Market Growth
Attention Deficit Hyperactivity Disorder Therapeutics Market is segmented by Stimulants, Non-stimulants, Pediatric, and Adolescents, Adults
Rising prevalence of ADHD across the globe, owing to the low threshold of diagnostic criteria, is expected to fuel revenue growth of the global attention-deficit hyperactivity disorder (ADHD) therapeutics market over the forecast period. The exact cause for ADHD is still unclear, although genetic influence is observed in most cases.
As per data released by the Centers for Disease Control and Prevention (CDC), in 2016, approximately 6.1 million individuals (9.4%), which includes 388,000 children aged 2–5 years, 4 million children aged 6–11 years, and 3 million children aged 12–17 years, were diagnosed with ADHD in the U.S. Besides, boys are more likely to be diagnosed than girls (12.9% as compared to 5.6%) with ADHD.
Prevalence of ADHD is rising at an alarming rate, which is expected to fuel revenue growth of global attention-deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder.
Find Out More about the Report Coverage
- Pfizer Inc.
- Eli Lilly and Company
- Novartis AG
- GlaxoSmithKline PLC
- Mallinckrodt Pharmaceuticals
- Hisamitsu Pharmaceutical Co., Inc.
- Johnson & Johnson
- UCB S.A.
- Purdue Pharma L.P.
Continuous Innovation by ADHD drug manufacturers Anticipated to Accelerate Revenue Growth
Manufacturers are focusing on both, ADHD children and adults. For children, drugs are introduced with various features such as added flavours for easy consumption, while for adults, the focus is on providing a long-lasting effect to avoid the consumption of multiple pills a day. For example, Adzenys (amphetamine)—a fruit-flavoured chewable form pill—is manufactured by Neos Therapeutics for children.
It also comes in blister packs rather than a pill bottle, and thus facilitates quick and convenient use. Manufacturers are also focusing on offering products such as stimulants and non-stimulants, comparatively at lower costs. This will lead to the growth of the attention-deficit hyperactivity disorder therapeutics market in untapped regions such as APAC and MEA, which can successfully contribute to overall revenue generation in the global ADHD therapeutics market.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Growth Opportunity in North America and Europe
North America is expected to dominate the global attention-deficit hyperactivity disorder therapeutics market due to growing research & development activities and an increasing number of established players in the ADHD market. Europe is anticipated to be the second-most leading region in the attention-deficit hyperactivity disorder therapeutics market due to the presence of massive pharmaceutical companies in the region.
In Europe, Germany will lead the ADHD therapeutics regional market due to the presence of strong distributors and sales channels. Besides, increasing the sales force is also likely to expand product reach across these two regions through distribution & collaboration agreements. These opportunities will lead to market growth of ADHD therapeutics systems in these regions.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Contraindications & Side-effects Associated with ADHD Drugs May Hamper Overall Growth
Despite all the advantages, contraindications and side-effects associated with ADHD drugs are hampering the quality of life of patients, which is expected to hamper revenue growth of the attention-deficit hyperactivity disorder therapeutics market over the forecast period.
Contraindications such as allergic reaction to a molecule or any other medicine, medical conditions such as coronary artery disease, bipolar disorder, blood vessel problems, hypertension, kidney disease, seizures, pancytopenia, mydriasis, thrombocytopenic purpura, and visual disturbances, are associated with ADHD drugs.
Side-effects such as hallucinations, fast or irregular heartbeat, severe nausea or vomiting, seizure, impotence, numbness, burning, or tingling, decreased appetite, severe headache, upper abdominal and stomach pain, and weight loss are associated with ADHD drugs.
A large number of contraindications and side-effects associated with ADHD drugs is limiting prescriptions based on the medical condition of patients, which is expected to hamper revenue growth.
Explore Persistence Market Research’s expertise in promulgation of the business !
Competitive Landscape of ADHD Therapeutics Market
The global attention-deficit hyperactivity disorder therapeutics market is a highly fragmented market space, with a huge number of manufacturers present in the market. Key players operating in the attention-deficit hyperactivity disorder therapeutics market across the globe include Pfizer Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, UCB S.A., Hisamitsu Pharmaceutical Co., Inc., and Purdue Pharma L.P., among others.
Manufacturers are focusing on mergers, acquisitions, and partnerships to expand their product portfolios and increase revenue in different geographies. For instance, in September 2018, Tris Pharma Inc. acquired NextWave Pharmaceuticals and expanded its ADHD portfolio.
Impact of COVID-19 on ADHD Therapeutics Market
The COVID-19 pandemic is certainly a difficult time for individuals with attention-deficit hyperactivity disorder, owing to their vulnerability to the distress caused by the pandemic and physical distancing measures. As a result of these measures, individuals with ADHD might exhibit increased behavioral problems. On the back of this, ADHD therapeutics will witness significant growth in sales.
Furthermore, consumers panic buying essentials as a precautionary measure has resulted in essential medicines going out of stock, thereby driving players to deploy a new batch of medicines. This stands true for ADHD therapeutics as well.
The demand for ADHD therapeutics is further surging, as face-to-face sessions and hospital visits of all non-essential medical conditions have been postponed, thus making individuals with ADHD solely reliant on medicines.
The research report on ADHD therapeutics market provides recommendations, overview of the market, and estimation of market growth over the next decade. Growing prevalence of attention deficit hyperactivity disorder, higher adoption of generic medication, and introduction of new patient-specific ADHD drugs are responsible for the growth of the attention-deficit hyperactivity disorder therapeutics market.
North America and Europe hold a substantial share of the global ADHD therapeutics market. Increasing introduction of innovative ADHD therapeutic products such as fruit-flavored chewable pills for children will favor the growth of the global attention-deficit hyperactivity disorder therapeutics market.
Key Segments of ADHD Therapeutics Market
PMR’s study on the attention-deficit hyperactivity disorder therapeutics market offers information divided into four important segments - drug type, age group, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Key Questions Answered in Report
- How much is the Attention Deficit Hyperactivity Disorder Therapeutics market worth?
The global attention deficit hyperactivity disorder therapeutics market is estimated to be worth US$ 22.5 Bn in the year 2021.
- What will be the demand outlook?
The attention deficit hyperactivity disorder therapeutics market is expected to grow twofold between 2021 and 2031.
- What was the last 5 year market CAGR?
The attention deficit hyperactivity disorder therapeutics market witnessed a CAGR of 6% between 2021 and 2031.
- What are the key trends of attention deficit hyperactivity disorder therapeutics market?
As of now, the players are focusing on introducing attention deficit hyperactivity disorder drugs for both – adults and children.
- What is driving the demand for attention deficit hyperactivity disorder therapeutics?
Rising incidences of attention deficit hyperactivity disorders are driving the demand for attention deficit hyperactivity disorder therapeutics.
- What is the market share of top 5 players?
The top 5 players such as Pfizer Inc., Eli Lilly and Company, Novartis AG, GlaxoSmithKline PLC, and Mallinckrodt Pharmaceuticals hold more than 50% of the market share.
- What are the top 5 countries driving demand?
The top 5 countries driving demand include the US, UK, Germany, Russia, and India.
- What is North America’s market Outlook?
North America holds more than 30% of the market share in terms of revenue due to the US.
- At what percentage attention deficit hyperactivity disorder therapeutics market is going to register growth in Europe?
Europe is expected to register growth at the rate of 6% in the attention deficit hyperactivity disorder therapeutics market between 2021 and 2031.
- Which are the key exporters of attention deficit hyperactivity disorder drugs?
The US, Germany, and the UK are the key exporters of attention deficit hyperactivity disorder drugs.